- Home
- NPCE vs XOMA Comparison
NPCE vs XOMA Comparison
Compare NPCE & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- XOMA
- Stock Information
- Founded
- NPCE 1997
- XOMA 1981
- Country
- NPCE United States
- XOMA United States
- Employees
- NPCE N/A
- XOMA N/A
- Industry
- NPCE Medical Specialities
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- XOMA Health Care
- Exchange
- NPCE Nasdaq
- XOMA Nasdaq
- Market Cap
- NPCE 355.5M
- XOMA 355.6M
- IPO Year
- NPCE 2021
- XOMA N/A
- Fundamental
- Price
- NPCE $11.97
- XOMA $26.76
- Analyst Decision
- NPCE Buy
- XOMA Strong Buy
- Analyst Count
- NPCE 6
- XOMA 2
- Target Price
- NPCE $15.83
- XOMA $81.50
- AVG Volume (30 Days)
- NPCE 86.9K
- XOMA 36.4K
- Earning Date
- NPCE 03-04-2025
- XOMA 03-07-2025
- Dividend Yield
- NPCE N/A
- XOMA N/A
- EPS Growth
- NPCE N/A
- XOMA N/A
- EPS
- NPCE N/A
- XOMA N/A
- Revenue
- NPCE $76,452,000.00
- XOMA $21,606,000.00
- Revenue This Year
- NPCE $23.46
- XOMA $511.48
- Revenue Next Year
- NPCE $14.64
- XOMA $26.91
- P/E Ratio
- NPCE N/A
- XOMA N/A
- Revenue Growth
- NPCE 27.00
- XOMA 389.82
- 52 Week Low
- NPCE $5.45
- XOMA $18.57
- 52 Week High
- NPCE $18.15
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- NPCE 58.55
- XOMA 47.49
- Support Level
- NPCE $11.37
- XOMA $23.88
- Resistance Level
- NPCE $12.65
- XOMA $29.02
- Average True Range (ATR)
- NPCE 0.96
- XOMA 1.27
- MACD
- NPCE -0.05
- XOMA 0.27
- Stochastic Oscillator
- NPCE 48.94
- XOMA 56.03
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.